Novo Nordisk A/S (NYSE: NVO) plans to limit starter kit supplies of Ozempic (semaglutide) in Europe and reduce the distribution of Victoza (liraglutide), aiming to bolster Ozempic's production, which has experienced a
Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this
Goldman Sachs downgraded Incyte Corp (NASDAQ: INCY), citing continued uncertainty around Jakafi (Ruxolitinib) lifecycle management ahead of the mid-27/late-28 EU/US
Connect Biopharma Holdings Limited (NASDAQ: CNTB) released topline results from Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart's (formerly known as CBP-201) efficacy and safety in patients with moderate-to-
Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of
Moderna Inc (NASDAQ: MRNA) shares slipped on Tuesday trading after the European Patent Office said a contested mRNA patent owned by Moderna is invalid, marking a victory for Pfizer Inc (NYSE: PFE) /
MorphoSys AG (NASDAQ: MOR) released topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve
Silo Pharma Inc (NASDAQ: SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo's intranasal therapeutic drug SPC-15.